[Close X]

RESPIRATORY

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 UNICONTIN® -E CR THEOPHYLLINE ANHYDROUS 400 / 600mg ANTI-ASTHMATIC
2 PHYLLOCONTIN® CR AMINOPHYLLINE 225/350 mg ANTI-ASTHMATIC
3 CEBOFYL® ACEBROPHYLLINE 100MG FOR C.O.P.D.
4 ACOCONTIN® CR AMBROXOL HYDROCHLORIDE 75mg MUCOLYTIC
5 ACOLYT ® AMBROXOL HYDROCHLORIDE 30mg/5ml MUCOLYTIC

CARDIOVASCULARS

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 NITROCONTIN® CR NITROGLYCERIN 2.6 / 6.4mg ANTI-ANGINAL
2 DILCONTIN™ 60 CR DILTIAZEM HCI 60mg TWICE-A-DAY ANTI-ANGINAL/ANTIHYPERTENSIVE
3 DILCONTIN™ XL CR DILTIAZEM HCI 90/120/180mg ONCE-A-DAY ANTI-ANGINAL/ANTIHYPERTENSIVE
4 INDICONTIN® CR INDAPAMIDE 1.5 mg ANTI-HYPERTENSIVE

UROLOGICALS

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 TAMCONTIN® CR TAMSULOSIN 0.4/0.2 mg FOR BPH
2 TAMCONTIN® -D CR TAMSULOSIN 0.4/mg with DUTASTERIDE 0.5 mg FOR BPH

GYNAECOLOGICALS

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 FECONTIN-F® CR FERROUS GLYCINE SULPHATE EQUIVALENT TO

100mg ELEMENTAL IRON WITH 0.5mg FOLIC ACID
HAEMATINIC IN IRON DEFICIENCY
2 FECONTIN®-Z CR FERROUS GLYCINE SULPHATE EQUIVALENT TO

100mg IRON WITH CR ZINC SULPHATE

MONOHYDERATE 61.8mg & 0.5mg FOLIC ACID
HAEMATINIC DURING PREGNANCY & LACTATION
3 PYRICONTIN™ CR PYRIDOXINE HCI 100mg MANAGEMENT OF PRE-MENSTRUAL SYNDROME
4 PYRICONTIN™-F CR PYRIDOXINE HCI 100mg & FOLIC ACID 5 mg ANTI-FERTILITY

ANALGESICS/NSAIDs

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 MORCONTIN® CR MORPHINE SULPHATE 10/30/60/100mg ANALGESIC
2 TRD-CONTIN® CR TRAMADOL HCL 100mg TWICE A DAY ANALGESIC
3 TRD-MD™ TRAMADOL MOUTH DISPERSIBLE 50 mg ANALGESIC
4 TRD-P® TRAMADOL 37.5mg & PARACETAMOL 325 mg ANALGESIC
5 FENAPLUS™ DICLOFENAC SODIUM 50mg WITH

PARACETAMOL 500mg
ANALGESIC/ANTI-INFLAMMATORY
6 FENAPLUS™ MR ENTERIC COATED DICLOFENAC SODIUM 50mg WITH

500 mg PARACETAMOL 500mg CHLORZOXAZONE
ANALGESIC/ANTI-INFLAMMATORY

WITH MUSCLE RELAXANT

NUTRITIONAL

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 SOYGROWTH™ ISOLATED SOY PROTEIN POWDER NUTRITIONAL SUPPLEMENT

OTHERS

SR. NO. BRAND ACTIVE INGREDIENT THERAPEUTIC USE
1 METOCONTIN® CR METOCLOPRAMIDE HCI 15mg GASTRO-PROKINETIC
2 FLOXICONTIN® -O CR OFLOXACIN 400/800/600mg ANTI-BACTERIAL
Umesh Modi Group

Modi-Mundipharma Pvt. Ltd.

With the staggering success of Win-Medicare, Mr. Umesh K. Modi felt the need to expand his pharmaceutical business further. And was born Modi–Mundipharma in 1990. It is a 50:50-joint venture between the privately held Mundipharma Group of Switzerland (known as Purdue Pharma in USA and Napp Laboratories in UK) and Mr. Umesh K. Modi. One of the largest, privately held pharmaceutical company in India today, it is ranked 8th among the multinational pharmaceutical corporations in India and 35th among the total of multinational and Indian pharmaceutical companies in India (Source: ORG IMS MAT DEC 10). The Company has a robust team totaling 1500 marketing and sales network professionals. It is effectively represented in the domestic and International markets including Asian, East African, Middle East markets & CIS Countries.

A rapidly growing pharmaceuticals company, Modi-Mundipharma draws its primary strength from sound research and development as well as existing formulations of the Mundipharma group of companies, world wide. Modi-Mundipharma offers world renowned formulations in various therapeutic segments, encompassing cardiology, respiratory, gynaecology, pain, heart diseases and other chronic therapy segments.

RESPIRATORY View Product Portfolio
CARDIOVASCULARS View Product Portfolio
UROLOGICALS View Product Portfolio
GYNAECOLOGICALS View Product Portfolio
ANALGESICS/NSAIDs View Product Portfolio
NUTRITIONAL View Product Portfolio
OTHERS View Product Portfolio

Medical fraternity, across the length and breadth of India, perceive Modi-Mundipharma to be a pharmaceutical company that offers long acting formulations in specialised therapeutic segments. It has reached this position with consistent exposure of the brand benefits derived from Continus controlled drug delivery, the  differentiated and unique New Drug Delivery System (NDDS) endorsed by medical practitioners across 70 countries world over.

A research & development collaboration agreement has been signed between Modi-Mundipharma, India and Mundipharma Laboratories GMBH under which Modi-Mundipharma will undertake development of product formulations for Purdue Pharma.

The focus of Modi-Mundipharma is to continue offering state-of-the-art and latest high-tech pharmaceutical solutions through introduction of differentiated products in the field of respiratory, pain and heart diseases. It is effectively represented in the domestic and South Asian markets.

Modi-Mundipharma markets:

  • Largest Nitrate brand in India
  • Second Largest O.S. Tramadol brand in India
  • Largest Plain O.S. Tramadol brand in India

Under its wing Modi-Mundipharma group has:

  • Win-Medicare Pvt. Ltd.; a subsidiary.
  • Win Healthcare; OTC arm of Win Medicare.
  • Mundipharma (Bangladesh) Pvt. Ltd.; a wholly owned subsidiary. (1st international pharma plant of the group)
  • Modi-Revlon Pvt. Ltd., under which is
    • # Revlon Trading Bangladesh Pvt. Ltd.; a wholly owned subsidiary of Modi-Revlon.
    • # Revlon Lanka (Pvt.) Ltd.; a wholly owned subsidiary of Modi-Revlon.
    • # Kamakhya Cosmetics & Pharmaceuticals Pvt.Ltd.
  • Modi Omega; JV Collaboration between Modi Mundipharma & Omega.

Its licensing partners are:

  • Merz Pharmaceuticals, Germany
    In licensing arrangement with Merz & Co. GMBH, Germany, for marketing:
    • HepaMerzTM, for hepatotherapeutics;
    • Axura® for Alzheimer’s disease and
    • Contractubex® & Mederma® for treatment of scars.
  • Tillotts Pharma AG, Switzerland
    In licensing arrangement with Tillotts Pharma AG, Switzerland, for marketing:
    • Asacol®, a product for management of ulcerative colitis.
  • IBSA - Institut Biochimique SA, Switzerland
    In licensing arrangement with IBSA - Institut Biochimique SA, Switzerland, for marketing:
    • Corion®, Pregnorm®, and Gonatrop® F, the infertility management range.
  • Pierre Fabre France
    In licensing arrangement with Pierre Fabre, France, for marketing:
    • Eludril®
    • Arthrodont®
    • Pansoral®
    • Elugeltm
    • Elgydium®
  • Sigma Tau, Italy
    In licensing arrangement with Sigma Tau, Italy, for marketing:
    • Carnitor®, for managing primary & secondary carnitine deficiency states.
  • Zambon,Italy
    In licensing arrangement with Zambon, Italy, for marketing:
    • Fluimicil® - For Respiratory Portfolio
    • Monurol® - For Managing UTI.
  • Norgine UK
    In licensing arrangement with Norgine, UK, for marketing:
    • Movicol®
    • Moviprep®
  • TRIGO Care International GMbH, Germany
    In licensing arrangement for marketing:
    • Diagnopad™ – Diagnostic kit for early detection of Diabetic Neuropathy.
  • Orion, Finland
    In licensing arrangement with Orion, Finland for marketing:
    • Divigel® – For Hormone replacement Therapy.


R & D Facility

Mundipharma Plant
Modi-Mundipharma

Anti Corruption Policy
Modi-Mundipharma


Compliance Hotline details :

Telephone (Toll free):
1800-103-4111


HR Gallery :

1. About HR
2. Code of Ethics
4. Career